Dr Reddy's Acquires Progynova, Cyclo-Progynova Brands from Mercury Pharma
Hyderabad: Dr. Reddy's Laboratories Ltd. has announced the acquisition of the trademarks for specialty brands Progynova and Cyclo-Progynova, along with related assets, for the Indian market from Mercury Pharma Group Limited, a UK-headquartered specialty pharmaceutical company.
Progynova® (estradiol valerate) is an oral hormone replacement therapy (HRT) indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova® (estradiol valerate and norgestrel) is a combined HRT therapy indicated for estrogen deficiency symptoms, providing both estrogen and progestogen components.
According to IQVIA MAT December 2025 data, Progynova® recorded sales of approximately ₹100 crore in India. The brand is ranked number one in the estradiol-represented pharmaceutical market (RPM) and enjoys strong physician recall and equity.
The acquisition marks Dr. Reddy’s strategic entry into the hormone replacement therapy segment and strengthens its gynaecology portfolio in India.
Commenting on the development, M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said, “The acquisition will serve as the spearhead of our expansion into the HRT segment, strengthening our existing gynaecology portfolio in India. With our established market access, we are uniquely positioned to extend the reach of the acquired assets and deliver greater impact. Furthermore, this acquisition brings a first-in-class treatment closer to patients, underscoring our commitment to innovation and patient care at the centre of everything we do.”
Dr. Reddy’s Laboratories Ltd. is a Hyderabad-based global pharmaceutical company engaged in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. The company operates across major markets including the United States, India, Russia & CIS countries, China, Brazil, and Europe.
Also Read: Dr Reddy's Foils Email Spoofing Scam, Rs 2.16 Cr Recovered by Bengaluru Police
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.